# Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors

> **NCT00659126** · PHASE2 · TERMINATED · sponsor: **OHSU Knight Cancer Institute** · enrollment: 40 (actual)

## Conditions studied

- Metastatic Malignant Neoplasm in the Brain
- Primary Brain Neoplasm

## Interventions

- **PROCEDURE:** 3 Tesla Magnetic Resonance Imaging
- **PROCEDURE:** Dynamic Contrast-Enhanced Magnetic Resonance Imaging
- **PROCEDURE:** Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
- **DRUG:** Ferumoxytol
- **DRUG:** Gadolinium
- **PROCEDURE:** High Field Strength Magnetic Resonance Imaging
- **PROCEDURE:** Susceptibility Weighted Imaging

## Key facts

- **NCT ID:** NCT00659126
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-11-16
- **Primary completion:** 2019-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Loss of funding
- **Last updated:** 2023-09-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00659126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00659126, "Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT00659126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*